| Literature DB >> 35042938 |
Sebastian Heller1, Ana Nanette Tibubos2, Thilo A Hoff1, Antonia M Werner3, Jennifer L Reichel1, Lina M Mülder4, Markus Schäfer5, Daniel Pfirrmann6, Birgit Stark5, Thomas Rigotti4, Perikles Simon6, Manfred E Beutel3, Stephan Letzel1, Pavel Dietz7.
Abstract
Aiming to develop and implement intervention strategies targeting pharmacological neuroenhancement (PN) among university students more specifically, we (1) assessed the prevalence of PN among German university students, (2) identified potential sociodemographic and study-related risk groups, and (3) investigated sociodemographic, psychological, study-related psychosocial, general psychosocial and health behavior related factors predicting the 12-month prevalence of PN. Therefore, a cross-sectional online survey was administered to students of the University of Mainz, Germany. A binary logistic regression with stepwise inclusion of the five variable groups was performed to predict PN. A total number of 4351 students out of 31,213 registered students (13.9%) participated in the survey, of which N = 3984 answered the question concerning PN. Of these, 10.4% had used one substance for PN at least once in the past 12 months. The regression analysis revealed 13 variables that were significantly related to the 12-month prevalence of PN. Specifically, the group of health behavior related variables showed the strongest relationship with PN. Therefore, an approach to the prevention of PN should be multifactorial so that it addresses social conditions, as well as education on substance use and healthy behaviors in terms of non-pharmacological strategies as alternatives of PN.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35042938 PMCID: PMC8766436 DOI: 10.1038/s41598-022-04891-y
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Characteristics of the study sample and values for the 12-month prevalence of pharmacological neuroenhancement distributed for sociodemographic and study-related characteristics.
| Variable | Value | |||
|---|---|---|---|---|
| Total sample | 12-month PN users | PN non-users | ||
| All, | 3984 (100.0) | 416 (10.4) | 3384 (84.5) | |
| (a) Female | 2842 (71.3) | 263 (9.3) | 2458 (86.5) | a-b |
| (b) Male | 1110 (27.9) | 146 (13.2) | 903 (81.4) | |
| (c) Diverse | 32 (0.8) | 7 (21.9) | 23 (71.9) | |
| 16–73 (23.8 ± 4.3) | 18–52 (23.6 ± 3.9) | 16–73 (23.7 ± 4.3) | ||
| 1–45 (7.2 ± 4.8) | 1–24 (6.6 ± 4.5) | 1–45 (7.2 ± 4.8) | ||
| (a) Younger or equal 23 years | 2243 (56.4) | 233 (10.4) | 1929 (86.0) | |
| (b) Older than 23 years | 1737 (43.6) | 182 (10.5) | 1452 (83,6) | |
| (a) Yes | 650 (16.3) | 79 (12.2) | 554 (85.2) | |
| (b) No | 3228 (81.0) | 320 (9.9) | 2747 (85.1) | |
| (a) STEM | 720 (18.1) | 65 (9.0) | 628 (87.2) | a-b; b-f; e–f |
| (b) Social sciences, media or sport | 717 (18.0) | 89 (12.4) | 598 (83.4) | |
| (c) Philosophy, humanities or cultural sciences | 803 (20.2) | 89 (11.1) | 674 (83.9) | |
| (d) Medicine | 528 (13.3) | 51 (9.7) | 439 (83.1) | |
| (e) Law or economics | 512 (12.9) | 63 (12.3) | 432 (84.4) | |
| (f) Aspiring teachers | 614 (15.4) | 50 (8.1) | 537 (87.5) | |
| (a) Bachelor | 2086 (52.4) | 254 (12.2) | 1734 (83.1) | a-b; a-d; b-c; c-d |
| (b) Master | 844 (21.2) | 63 (7.5) | 751 (89.0) | |
| (c) State examination | 876 (22.0) | 91 (10.4) | 738 (84.2) | |
| (d) Doctorate | 139 (3.5) | 5 (3.6) | 126 (90.6) | |
‘12-month PN users’: respondents who used pharmacological neuroenhancement within the last 12 months; ‘PN non-users’: respondents who did not use pharmacological neuroenhancement within the last 12 months; alphabetic characters ‘a-b’; ‘a-d’; ‘b-c’; ‘c-d’ represent significant differences (p < 0.05) in the prevalence of ‘12-month PN users’ between respective categories of that variable. Note that the category ‘more than 12 month ago’ for the prevalence of pharmacological neuroenhancement (n = 184) is not presented in this table; SD: standard deviation; #: age dichotomized at the median; STEM: science, technology, engineering, and mathematics.
Prevalences for the use of illicit or prescription drugs for pharmacological neuroenhancement among students at the University of Mainz (n = 3984).
| Use of any surveyed substance | Never used | Used | |||
|---|---|---|---|---|---|
| Total responses | Within the last month | Within the last 12 months | More than 12 months ago | ||
| Methylphenidate | 97.1% ( | 2.9% ( | 0.7% ( | 0.7% ( | 1.6% ( |
| Amphetamine preparation | 99.6% ( | 0.4% ( | 0.1% ( | 0.1% ( | 0.8% ( |
| Atomoxetine | 99.8% ( | 0.2% ( | 0.1% ( | < 0.1% ( | < 0.1% ( |
| Modafinil | 99.5% ( | 0.5% ( | 0.2% ( | 0.1% ( | 0.1% ( |
| Ecstasy (MDMA) | 98.3% ( | 1.7% ( | 0.3% ( | 0.6% ( | 0.7% ( |
| Ephedrine | 99.6% ( | 0.4% ( | 0.1% ( | 0.2% ( | 0.2% ( |
| Cocaine | 98.7% ( | 1.3% ( | 0.2% ( | 0.4% ( | 0.7% ( |
| Amphetamine | 98.2% ( | 1.8% ( | 0.4% ( | 0.5% ( | 0.9% ( |
| Crystal Meth | 99.9% ( | 0.1% ( | < 0.1% ( | 0.1% ( | < 0.1% ( |
| Cannabis | 89.3% ( | 10.7% ( | 3.6% ( | 3.6% ( | 3.6% ( |
| Other substances | 96.9% ( | 3.1% ( | 1.4% ( | 0.9% ( | 0.8% ( |
Range of missing cases among drugs for pharmacological neuroenhancement = 1–2.
Significant predictors of the 12-month prevalence of pharmacological neuroenhancement in a binary logistic regression analysis with stepwise inclusion of the 5 independent variable groups: sociodemographic, psychological, study-related psychosocial, general psychosocial and health behavior related variables.
| OR (95% CI); ‘reference category’ | ||
|---|---|---|
| Gender—male | 1.387 (1.052–1.827); ‘female’ | 0.02 |
| Depressive symptoms | 1.086 (1.044–1.129) | < 0.001 |
| Absenteeism | 1.022 (1.005–1.040) | 0.01 |
| Social support (fellow students) | 0.830 (0.721–0.955) | 0.009 |
| Self-criticism | 0.955 (0.926–0.986) | 0.004 |
| Healthy diet | 1.264 (1.117–1.431) | < 0.001 |
| Moderate-vigorous physical activity (min/day) | 1.001 (1.000–1.002) | 0.011 |
| Alcohol use | 1.612 (1.243– 2.092) | < 0.001 |
| Smoking cigarettes | 1.468 (1.349–1.597) | < 0.001 |
| Coffee | ||
| Within the last 30 days | 1.531 (1.114–2.106); ‘never’ | 0.009 |
| Caffeine tablets | ||
| Within the last 30 days | 4.235 (2.552–7.027); ‘never’ | < 0.001 |
| Within the last 12 months | 1.763 (1.011–3.073); ‘never’ | 0.046 |
| More than 12 months ago | 2.117 (1.416–3.164); ‘never’ | < 0.001 |
| Coke | ||
| Within the last 30 days | 1.669 (1.255–2.221); ‘never’ | < 0.001 |
| Within the last 12 months | 2.267 (1.587–3.239); ‘never’ | < 0.001 |
| Ginkgo biloba | ||
| Within the last 30 days | 2.587 (1.164–5.747); ‘never’ | 0.02 |
Observed cases: n = 3608; R = 0.257; χ (40) = 490.590; p < 0.001; please find results of the binary logistic regression model for all included (significant and non-significant) variables in Supplementary Table 4.